SUMMARY. A prerequisite of current therapy in liver disease is precise diagnosis. The rapid increase in the number of tests available-immunological, virological, histological and radiological-testifies to this, and reflects the inadequacy of the 'standard' liver function tests (LFTs). The LFTs are, however, in contrast to these more sophisticated tests, observer independent and despite their lack of specificity, several characteristic patterns of abnormality can be recognised which direct the physician to the most appropriate definitive investigation. The cheapness and non-invasive nature of the LFTs makes them particularly appropriate for monitoring the course ofliver diseases once the diagnosis has been established and this, together with screening for hepatotoxicity of newly developed drugs, is now their main role. A second generation of liver function tests based on the capacity of the liver to eliminate various test compounds may come closer to offering a true estimate of liver function. More accurate methods of measuring the various bilirubin fractions, particularly bilirubin conjugates may also become available in the near future and provide more sensitive tests of liver dysfunction.
Numerous laboratory investigations have been proposed in the assessment ofliver disease. From among these, the following battery of blood tests: total bilirubin; certain enzymes: aminotransferases, alkaline phosphatase and y-glutamyitransferase; and total protein and albumin, have become widely known as the standard 'liver function tests' (LFTs). Urine tests for bilirubin and its metabolites and the prothrombin time are also often included under this heading, but tests such as thymol turbidity and bromsulphalein clearance are now outmoded. 'Second generation' LFTs attempt to improve on this battery of tests and to gain a genuine measurement of liver function, i.e. a quantitative assessment of functional hepatic mass. These include the capacity of the liver to eliminate exogenous compounds such as aminopyrine, or caffeine, or endogenous compounds such as bile acids.'> Such investigations are not yet used routinely or widely and this review concentrates on the 'standard' tests of liver function listed above.
Whilst it has long been appreciated that such a designation is really a misnomer since these tests do not measure liver function in any quantitative sense being concerned mainly with liver dysfunction, the term seems destined to survive. Nonetheless, with the advent of more sophisticated techniques for the diagnosis of liver disease, particularly ultrasound and CT scanning, together with percutaneous and endoscopic cholangiography and liver biopsy, their routine use is being questioned. The critical physician will readily admit that, faced with a patient suspected of having liver disease, the results of the LFTs do not always advance the differential diagnosis established by a careful clinical examination.
To obtain maximum information we need to be aware not just of the significance of the individual tests, but also of patterns of abnormalities and how they may change with time in a particular disease. This review considers first the individual tests, and then the characteristic changes in patterns seen in certain common clinical conditions and their prognostic implications. This paper was prepared at the invitation of the Clinical Laboratory Investigation Working Party of the Scientific Committee of the Association of Clinical Biochemists, but does not necessarily reflect their views.
Serumbilirubin
The concentration of bilirubin in the serum of an individual is determined by the balance between production and clearance. More than 95% of an apparently normal adult population have serum bilirubin concentrations below 25 Jlmol/L and this figure is usually considered the upper limit of 'normal'.' Hyperbilirubinaemia above 50 Jlmol/L can be detected as jaundice by experienced observers and when in excess of 100 Jlmol/L patients' relatives may notice. An increase in production of bilirubin, such as occurs in haemolytic anaemias, leads to hyperbilirubinaemia but since there is a limit to the compensatory increase in red cell production that can be achieved by the marrow (about 8-fold), the bilirubin concentration does not rise above 75 Jlmol/L.4 However, a haemolytic element may contribute to the much greater degree of hyperbilirubinaemia which can occur in conditions such as alcoholic hepatitis ('Zieve's syndrome') and Wilson's disease where there is, in addition to increased bilirubin production, a decrease in clearance.
CONJUGATED AND UN CONJUGATED BILIRUBIN
It is in these complicated situations, when the degree of jaundice appears out of proportion to the extent of the liver disease, and in certain congenital hyperbilirubinaemic syndromes, that estimating the conjugated ('direct-reacting') and unconjugated ('indirect-reacting') fractions may be useful. These fractions are usually estimated by a method based on the Van den Bergh reaction which relies on the different reaction of the two fractions with diazotised sulphanilic acid in the presence or absence of alcohol. While there is no doubt about the clinical usefulness ofthis method its liInitations should be recognised. Within the normal range the test is not accurate in separating the two fractions, and it has recently been shown that there is not a precise relationship between 'indirect' and 'direct' and unconjugated and conjugated bilirubin respectively-'direct-reacting' levels overestimate conjugated bilirubin at low concentrations and underestimate it at high concentrations.' A third fraction, 'tightly' (possibly covalently) bound to albumin is now also recognised. This fraction persists in serum after bilirubin has disappeared from the urine."
The distinction between conjugated and unconjugated fractions also provides a useful classification of the congenital hyperbilirubinaemias. The former includes Dubin-Johnson and Rotor's syndrome and the latter Crigler-Najjar and Gilbert's syndrome. A hyperbilirubinaemia is considered unconjugated when less than 20% of the total bilirubin is in the conjugated state. Of these only Gilbert's syndrome will be encountered frequently. Whilst entirely benign, recognition of the syndrome is important as the detection of jaundice during hospitalisation for some intercurrent illness invariably leads to diagnostic confusion particularly since the degree of hyperbilirubinaemia increases with fasting. Otherwise estimations of the separate bilirubin fractions is seldom required in adult practice though in paediatric practice the distinction is important in the management of neonatal jaundice (see below).
Although less than 500 mg of bilirubin is produced each day (from breakdown of haem, derived mainly from senescent red cells) the normal liver is capable of conjugating up to 1500 mg/day, This is one reason why hyperbilirubinaemia is an insensitive index of parenchymal liver disease. Thus whilst the serum bilirubin concentration may be a very specific test for liver disease, the diagnostic value of a single determination is limited. Requests for measurement of bilirubin should therefore be confined to situations where it is important to confirm a clinical impression of jaundice, monitor changes in response to therapy, or detect hyperbilirubinaemia that is suspected but not apparent clinically. Even in the latter situation a simple urine test for bilirubin will pick up conjugated hyperbilirubinaemia and, in acute hepatitis, detect incipient liver disease before the bilirubin starts to rise in the serum.
NEONATAL JAUNDICE
Normal full term babies may be jaundiced from the 2nd to the 8th day oflife and premature babies from the 2nd to 14th day. This 'physiological' jaundice, which seldom exceeds 100 Jlmol/L in the full term infant and 200 Jlmol/L in the premature, is unconjugated and attributable to a combination of factors: increased production and impaired uptake of bilirubin together with increased reabsorption from the gut. Jaundice detectable on the first day of life, or outside the ranges described above, is always pathological as is conjugated bilirubinaemia.
If the unconjugated bilirubin concentration exceeds 300 Jlmol/L in full-term infants there is a significant risk of kernicterus (brain damage due to uptake of unconjugated bilirubin) and treatment by phototherapy or exchange transfusion is indicated. Thus while measurement of serum bilirubin is not indicated as a routine in jaundiced neonates it is crucial to the management of any neonate with deepening jaundice. Separation into conjugated and unconjugated fractions gives use-ful clues as to its aetiology and the presence of dark urine is always an indication for further investigation (see below). The causes of conjugated hyper bilirubinaemia in infancy are legion but the crucial distinction between intrahepatic and surgically treatable extrahepatic causes (such as biliary atresia or choledochal cyst) cannot be made on the basis of standard LFTs but relies on the use of the l311-rose bengal faecal excretion test (or, of late, technetium-labelled hepatobiliary imaging agents) to determine the patency of the extrahepatic bile-ducts, and liver biopsy.
URINARY BILIRUBIN AND UROBILINOGEN
Urinary bilirubin can be reliably detected by the use of commercially available dipsticks and a positive test indicates hepatic dysfunction or biliary tract disease and, as noted above, may be present before bilirubin concentrations start to rise in the blood. The test remains an invaluable screening tool in general practice though in hospitals where there is usually ready access to serum estimations, it is less used. Accurate measurement of urinary urobilinogen concentrations is not so easy. In the past, the persistent absence of this urinary chromogen was taken as evidence of complete biliary obstruction, usually malignant in origin, but less time-consuming and more reliable radiological procedures have now replaced this approach.
The aminotraosferases
Elevated plasma activities of aspartate aminotransferase (AST) or alanine aminotransferase (ALT)--previously known as glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT), respectively-are presumed to result from leakage of the enzyme from damaged or necrotic cells." The origin of the normal circulating activity ofthese enzymes is not known but there are several other tissues besides liver (such as skeletal muscle, heart, red blood cells and kidney) from which they can be released. An elevated AST of up to about 10 times the upper limit of the reference range simply implies that liver cells have been damaged in some way, but gives no clue as to the site of the primary lesion. Very high values (more than 10 times the upper limit of the reference range) define the problem as primarily due to hepatocyte damage. Acute, chronic and drug induced (but not alcoholic) hepatitis are the primary hepatic conditions which commonly lead to values in this range though acute rhabdomyolysis, shock, cardiac failure and sepsis may also cause very high AST levels.
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Alkaline phosphatase (ALP) In contrast to the aminotransferases, increase in the activity of ALP in liver disease is due not to hepatocyte disruption, nor to a failure of clearance, but rather to increased synthesis of hepatic ALP,S the mechanism of which is now beginning to be unravelled." The stimulus for this increased synthesis in patients with liver disease is bile duct obstruction either extrahepatically by stones, tumour, or stricture or intrahepatically by infiltration or space occupying lesions. When other LFTs are normal, a high ALP strongly suggests a space occupying lesion. Physiological eventspregnancy, rapid bone growth in childhood and adolescence, and pathology at extrahepatic sites (bone disease in particular), may all lead to marked increases in ALP activity, and may be taken, incorrectly, as evidence of liver disease. Three main approaches to increase the specificity of the test for liver disease have been used. Starch or polyacrylamide gel electrophoresis reveal three distinct bands attributable to liver bone, and intestinal isoenzymes.v" In the face of high ALP activity it is usually obvious from inspection of the gels whether the increase is due to bone or liver. A separate placental band is seen during pregnancy, and occasionally in patients with extrahepatic malignancies (the so-called 'Regan' isoenzyme). About 30% of patients with primary liver cancer exhibit an additional 'hepatoma' isoenzyme which appears to be highly specific. The fraction of total ALP activity attributable to the various isoenzymes can also be assessed by different rates of inhibition with heat and L-phenylalanine.
The most widely adopted approach to confirming the hepatic origin of an elevated serum ALP activity is, however, to measure an additional enzyme which is elevated in liver but not bone disease. The two used most widely are 'l'GT (see below) and 5' nucleotidase (5'NT). When the activities of these two enzymes are elevated in the presence of a high ALP one can be confident that the ALP is of hepatic origin. Normal levels of 'l'GT and 5'NT do not necessarily imply that the ALP is of bone origin and for this reason isoenzyme fractionation is the more reliable, if more time-consuming, diagnostic test.
The activity of this microsomal enzyme is increased in most hepatobiliary diseases but, largely because of the enzyme's wide tissue distribution, the specificity of a high value is very low." The relation of the aminotransferase to ALP level may provide better evidence than either test alone as to whether or not the jaundice is cholestatic. High ALP with low aminotransferase activity is usual in cholestasis, and the converse occurs in non-cholestaticjaundice ( Fig. I) . However, even when the results are sufficiently extreme to make the distinction clear (Box D, Fig.  I) it must be remembered that there are several intrahepatic causes of cholestasis (such as primary biliary cirrhosis, acute alcoholic hepatitis, and sclerosing cholangitis) in which laparotomy abnormal the chance of there being significant disease of the hepatobiliary system rises rapidly, although as already mentioned young people may have a 'physiologically' elevated ALP of bone origin and when this occurs coincidentally with Gilbert's syndrome confusion may arise.
Having excluded these two causes the prime concern is to define those cases ofjaundice which need surgical intervention (extrahepatic biliary obstruction). This distinction cannot be made solely on the basis of LFfs which serve mainly to increase the confidence of the clinical appraisal and suggest the most appropriate next line of investigation.
Johnson
Unlike the aminotransferases elevated activities do not necessarily indicate liver cell disruption but may be due to enzyme induction by drugs (such as phenobarbitone, phenytoin and warfarin) or alcohol. These severe limitations have meant that this test now has only two practical uses. First, an elevated yGT implies that an elevated ALP is of hepatic origin, and second it may be useful in screening for alcohol abuse although as described below more specific tests are becoming available.
Serum albumin and total protein
The serum albumin concentration is widely regarded as an index of hepatic 'synthetic function' and in patients with liver disease a value below the lower limit of the reference range is taken to imply chronicity. This would indeed be the case were the rate of hepatic synthesis the only factor determining its serum concentration since the protein has a long serum half-life of about 3 weeks. However, several other factors including nutritional status, the rate of degradation, leakage of the protein into ascites and the extravascular compartment, and dilution due to fluid retention are also important. Some of these factors may change acutely and caution is advisable before hypoalbuminaemia is interpreted as a sign of decreased synthetic function or disease chronicity.
On the other hand, a normal serum albumin concentration probably does imply adequate synthetic function and whilst it has been reported that less than 15% of cirrhotic patients have albumin concentrations within the normal range" these data are probably based on patients hospitalised for acute decompensation. The vast majority of patients with cirrhosis are not in hospital and over 80% have a normal serum albumin.
Extreme hyperglobulinaemia is characteristic of chronic active hepatitis in young women and changes in globulin concentrations reflect disease activity. However, a reversed globulin:albumin ratio is not specific for liver disease and may occur in any chronic inflammatory state or renal disease. is inappropriate. Thus even after a confident diagnosis of cholestatic jaundice based on the LFTs, further investigation to define the site of obstruction is imperative.
Patterns of abnormality in tbe differential diagnosis of jaundice
In contrast, when the LFTs and clinical features are compatible with a hepatitic illness such as acute viral hepatitis (Box A, Fig. I ) further investigation is not always required and a case can often be made for simply observing events. If this course is to be followed it is important to understand the characteristic sequential changes that occur so that early referral for hospital investigation can be made should the expected course not ensue.
In acute viral hepatitis the serum aminotransferases always start to rise before jaundice, and often before hepatomegaly, is detectable. Activities start to fall coincidentally with the onset of jaundice and symptoms and return to normal (AST before ALT) at about the same time as the serum bilirubin. The alkaline phosphatase activity is seldom more than twice the upper limit of normal at presentation but it may rise much higher in that small group who enter a cholestatic phase after symptoms have subsided. Normal activities are achieved within 6 months and persistence of abnormal LFTs beyond this period defines the onset of chronic hepatitis." Progression to chronic hepatitis occurs only in hepatitis B ('serum') and Non-A Non-B, not in type A (infectious) hepatitis.
Liver fUJK:tion tests in alcohol abuse
From a clinical point of view we are interested in answering two questions. Firstly, does this patient whom we know to have an alcohol problem have liver disease, and if so, of what degree or at what stage? The definitive answer must rest on histological examination of liver tissue but since only a minority of alcoholics develop liver disease we cannot justify biopsy, a procedure with significant morbidity, in all. Of course, clinical features such as hepatomegaly, arterial spiders or oesophageal varices will point to liver involvement but these signs may be absent.
In this situation abnormalities of the LFTs have been considered reasonable grounds for undertaking a liver biopsy. However, when Galambos and Wills" investigated the relationship between paired LFTs and histological appearances in obese patients undergoing jejunoileal bypass, in which the spectrum of liver abnormalities is very similar to that found in alcoholic liver disease, they found the LFTs to be
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very non-specific and insensitive. Thus about 25% of those with 'any abnormal LFT' had normal histology, but if 'markedly' abnormal tests were required to justify liver biopsy, 'the majority of moderate to severe histological lesions would be missed'. Indeed, in several situations the frequency and severity of biopsy abnormalities were not different in those with or without abnormal LFTs. As already mentioned, yGT elevation probably reflects enzyme induction and does not, on its own, imply liver damage. Secondly, amongst an apparently healthy population, perhaps a company work force, can we detect those who have an alcohol problem? The best available test in this situation is yGTIS the activity of which will be elevated in about half to two thirds of those currently drinking more than 80 g of alcohol per day. Activities return to normal once drinking ceases, but the results should be interpreted with extreme caution since moderately elevated levels will be detected in several people who do not drink excessively, particularly in those taking enzyme inducing drugs. Nonetheless it is the author's experience that, faced with a documented abnormal yGT, several patients previously unaware that their drinking was reaching a dangerous level will readily limit or cease alcohol consumption. The combination of elevated activities of yGT and AST or of the mean corpuscular red cell volume (MeV) is more specific, but less sensitive.
Monitoring the course of diseases and response to therapy As implied above, the LFTs are oflimited value in diagnosis, and are being replaced by more definitive procedures. However once the diagnosis has been established certain LFTs come into their own. Quantitative estimation of bilirubin is of crucial importance in monitoring the progress of many diseases (particularly the clearance ofjaundice following relief of any obstruction) and in determining the point at which neonatal jaundice requires treatment to avoid the risk of kernicterus. It is also valuable in assessing the correct dose of cytotoxic drugs (such as doxorubicin) administered to patients with hepatic metastases. 16 Above 20 Jlmol/L severe pancytopaenia may occur if the drug dose is not reduced.
Sudden increases in yGT suggest a recent bout of drinking in alcoholics. The characteristic changes seen in acute hepatitis have already been referred to. Auto-immune chronic hepatitis responds well to immunosuppression in 90% of cases and such a response is indicated by return of year-old girl, Note that during an attempt to withdraw treatment the patient relapsed and that the AST (--) rose before and returned to normal after the bilirubin (---), indicating that it is a more sensitive marker ofliver damage, the LFTs, and particularly, AST, to the normal range. Monitoring LFTs gives early warning of impending relapse during attempts to withdraw treatment (Fig. 2) . The 'gold standard' must, however, remain histology since active disease may persist in the presence of near normal LFTs.
Monitoring drug hepatotoxicity
It is clearly desirable to detect impending acute or chronic liver damage attributable to drugs before clinical symptoms develop. However, in most cases reactions are unpredictable and occur only in a very small percentage of patients at risk. For this reason screening for abnormalities of LFTs is usually confined to trials of new drugs, and represents the most important method for early detection of hepatotoxicity. It should be noted however that abnormal LFTs are not always an indication for drug withdrawal. For example, about 10% of patients receiving isoniazid will develop raised aminotransferase levels, but these often return to normal despite continuation of the drug. During chemotherapy of liver tumours selective toxicity is the aim of therapy, and elevated levels of aminotransferases often herald a satisfactory clinical response.
Significance of abnormal LFfs in the absence of symptoms
Although the replacement ofmultichannel autoanalysers by discretionary systems will reduce the incidence of unrequested biochemical results reflecting occult liver disease, health screening programmes may provide an increasing source of unexpected biochemical abnormalities. Results suggesting liver disease occur in about I % of cases. Alcohol abuse is the commonest cause, though other forms of liver disease are also being picked up presymptomatically. The isolated finding of an elevated serum bilirubin in Gilbert's syndrome has already been mentioned and some 20% of our patients with primary biliary cirrhosis were diagnosed presymptomatically following accidental detection of an elevated ALP. Asymptomatic elevations of the AST are usually seen in obese individuals with a fatty liver in whom diabetes and alcohol abuse may be additional factors, though a small proportion will have conditions such as chronic active hepatitis or haemochromatosis which may benefit from early treatment. On this basis it has been suggested that all patients with asymptomatic elevations of AST should be investigated by liver biopsy.'? Nonethe-Serum bilirubin as a prognostic factor. less it is still not clear how often the therapeutic intervention offered outweighs the anxiety generated, the stress of consequent investigations and the implications for subsequent life assurance, particularly since a specific diagnosis is not always achieved and the diseases detected may not cause symptoms in the patient's lifetime. 
Prognostic implications
Whilst it is clearly one of the physician's duties to inform a patient of his prognosis even if there is no effective therapy available, patients usually request only the broadest of estimates. However, with the advent of orthotopic liver transplantation as a potentially curative treatment for previously fatal conditions, the accurate assessment of prognosis has become essential. Thus it becomes appropriate to offer a patient liver grafting when his prognosis becomes less than the current survival rate for the operation. Sophisticated statistical methods are now being widely applied to databases of clinical and biochemical features to generate prognostic equations for specific conditions and components of the standard LFfs figure prominently. For example, patients with primary biliary cirrhosis exhibit a normal concentration ofbilirubin in the early course of their disease. Once this starts to rise, survival is directly related to the absolute concentration (Table I) is greater than 6, then survival is likely to be less Survival is related to the depth of jaundice in patients with primary biliary cirrhosis. The bilirubin levels quoted had been exceeded for at least 6 months." than 6 months. (Serum bilirubin is in /lmoI/L, albumin in giL, and age in years.)
In patients with acute alcoholic hepatitis, the magnitude of the serum bilirubin concentration together with the prothrombin time are major independent risk factors associated with a high likelihood of death during that hospital admission."
In large scale studies, the concentration of serum albumin (often in combination with the ALP) is usually strongly correlated with survival in patients with parenchymal liver disease or hepatic metastases. For the individual patient, however, little prognostic significance can be attached to a single reading although rising bilirubin and falling albumin concentrations are ominous signs.
Will other tests join the 'LFTs'?
Newly developed tests are required to meet far more stringent criteria than were their predecessors. Serum bile acids (SBA) came close to being elected.! when simple and sensitive assays became available but while there is no doubt that an elevated SBA level is remarkably specific for liver disease, the test is no better than AST in detecting mild liver disease." Clearance tests such as the galactose elimination capacity and [l4C]aminopyrine breath test undoubtedly offer a better estimate of functioning hepatic mass, but in most clinical situations the information gained is not perceived as justifying the time and effort expended. They may however find a role in research situations such as monitoring results of new treatments" or in assessing the prognosis of patients considered for liver transplantation. Much evidence suggests that estimation of bilirubin conjugates in serum would be an extremely sensitive test of liver disease but simple automated methods are not yet available. ' In view of the steadily increasing incidence of alcoholic liver disease better tests for chronic alcohol ingestion are badly needed. Two new approaches are measurement of the mitochondrial fraction of serum AST23 and desialylated transferrin. Among patients chronically abusing alcohol the desialylated fraction exceeds 2% of the total transferrin.24
Conclusions
Perhaps the major and most frustrating problem with putative liver function tests is the lack of a real 'gold standard' by which to judge their efficacy. Histological analysis often assumes this role but it is not entirely clear why, in view of the problems with sampling error, inter-observer variation and its limited ability to quantitate abnormalities. Hofmann suggested the preeminence of histology relates to our natural preference for 'seeing' something '... seeing is believing: few parents would accept a blood or urine test as a replacement for direct inspection of their newly delivered baby to determine whether it was a boy or girl'.' Whether they would be pleased to rely on 'direct inspection' if this involved looking down a microscope at a 'blind' needle biopsy of their infant in the hope of finding diagnostic tissue is another matter.
As suggested at the outset, given sufficient time with the patient the presence of liver disease can often be ascertained with confidence on clinical grounds alone and LFTs serve only to confirm the clinical impression. To establish a precise diagnosis with sufficient confidence to embark on treatment little is lost in bypassing the standard LFTs and progressing directly to radiology, serology or biopsy, as appropriate. Indeed, of the simple laboratory tests, the hepatologist would often choose the prothrombin time in preference to the routine LFTs.
Regrettably, however, in the real world not all patients have a detailed history taken or examination performed and in this situation detection of abnormal LFTs may result in the patient being referred for a specialist opinion before signs and symptoms become gross. Even the purist might agree that, with the LFT results in hand whilst seeing the patient the clinicians' questions and examination may be more economically directed. In the present pressured clinical climate, such considerations should not be minimised. Nor should the simple observation that LFTs (unlike their more sophisticated radiological rivals) offer quick, cheap, easily stored and observer independent data. At a less pragmatic level, the conventional LFTs are valuable in screening for drug toxicity, monitoring the course of some liver diseases and response to therapy, and are components of several new and important prognostic indices. For all these reasons, the flood of LFT requests to the pathology laboratory will continue for some time to come.
